[Federal Register Volume 79, Number 116 (Tuesday, June 17, 2014)]
[Notices]
[Page 34552]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-14150]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: MEDA 
PHARMACEUTICALS, INC.

ACTION: Notice of Application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before July 17, 2014. Such persons may also file a 
written request for a hearing on the application pursuant to 21 CFR 
1301.43 on or before July 17, 2014.

ADDRESS: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, and dispensers of controlled substances 
(other than final orders in connection with suspension, denial, or 
revocation of registration) has been redelegated to the Deputy 
Assistant Administrator of the DEA Office of Diversion Control 
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR 
pt. 0, subpt. R, App.
    In accordance with 21 CFR 1301.34(a), this is notice that on 
December 9, 2013, Meda Pharmaceuticals, Inc., 705 Eldorado Street, 
Decatur, Illinois 62523, applied to be registered as an importer of 
Nabilone (7379), a basic class of non-narcotic controlled substance 
listed in schedule II.
    The company plans to import the FDA approved listed controlled 
substance as a finished drug product in dosage form for distribution to 
its customers.

    Dated: June 10, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-14150 Filed 6-16-14; 8:45 am]
BILLING CODE 4410-09-P